- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07629973
A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome (NEURDS)
Etude Des déterminants de l'évolution NEUrologique Des Patients Ayant présenté un Syndrome de Détresse Respiratoire aiguë
Acute respiratory distress syndrome (ARDS) is characterized by pathological pulmonary edema caused by direct or indirect damage to the alveolar-capillary membrane.
Its management relies on etiological treatment, invasive mechanical ventilation, and the use of sedatives and neuromuscular blockers, depending on the patient's condition.
Improvements in patient care have led to an improved prognosis. However, in-hospital mortality remains high (between 35% and 45%). Notably, morbidity among surviving patients is very high and is largely dominated by neuropsychological sequelae. Attention and executive function disorders, confusion, disorientation, or memory impairment are thus found in 70 to 100% of patients following ARDS. These disorders are still present in 46 to 80% of surviving patients one year after ARDS and in 20% of them five years later.
Although essential to treatment, mechanical ventilation carries a risk of significant complications. Beyond the risk of infection and complications related to sedation and neuromuscular blockade, the use of mechanical ventilation is associated with a risk of ventilator-induced lung injury (VILI).
The use of so-called protective ventilation reduces the risk of VILI and improves patient outcomes. However, analysis of relevant physiological parameters shows that the risk of VILI may still exist even when ventilator settings comply with recommendations and the concept of protective ventilation. Driving pressure (which represents Strain) is a good marker of VILI; it represents the distension of the lung with each breath relative to the initial lung volume. Values above 14 cmH₂O are associated with high mortality in patients with ARDS. Inspiratory transpulmonary pressure represents Stress-that is, the pressure that distends the alveoli at the end of inspiration-and is also associated with the risk of VILI. Finally, mechanical power represents the amount of energy delivered to the lung by the ventilator and has been validated as a marker of VILI. The advantage of mechanical power over the other indices described is that it incorporates all components that can lead to VILI.
Among the various sources of neurological damage during ARDS, inflammatory processes appear to play a major role. Numerous inflammatory mediators (TNF-α, IL-6, IL-8, IL-1β) are secreted during ARDS, and animal studies have demonstrated a link between inflammation and hippocampal damage. Furthermore, cerebral ischemic lesions, exacerbated by systemic inflammation and endothelial activation leading to coagulation activation with thrombus formation, may also contribute to the development of cognitive impairments.
In addition to the inflammatory processes associated with ARDS, mechanical ventilation itself may have a significant impact on neuroinflammatory damage. Recently, the term "ventilator-associated brain injury" (VABI) has been proposed to describe these secondary neurological lesions induced by mechanical ventilation. Studies in mouse and pig models have demonstrated a relationship between the dose and duration of VILI, apoptosis, neuroinflammation, and neuronal damage. An animal study in mice also showed an association between the duration of mechanical ventilation and the onset of cognitive impairments.
During brain injury, proteins and neurotransmitters are released and serve as biomarkers of brain damage. Elevated plasma levels of S100B protein indicate astrocyte damage caused by traumatic, anoxic-ischemic, or inflammatory mechanisms. It correlates with neurological prognosis following cardiac arrest, in ischemic or hemorrhagic strokes, in neurodegenerative diseases, and in patients with traumatic brain injury.
Clinical studies have shown a negative correlation between elevated S100B protein levels, the MoCA (Montreal Cognitive Assessment) score, and the MMSE (Mini-mental state evaluation ) in patients with OSA (Obstructive Sleep Apnea) or COPD (chronic obstructive pulmonary disease), respectively, indicating an association between this protein and cognitive impairment.
The investigators therefore hypothesize that mechanical ventilation associated with high mechanical power is linked to a significant risk of brain injury, reflected by elevated serum S100B protein levels and the presence of neurocognitive disorders long after ARDS.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: François Beloncle, Professor
- Telefonnummer: +33 2 41 35 38 15
- E-post: Francois.Beloncle@chu-angers.fr
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adult patient
- Patient admitted to the intensive care unit less than 48 hours ago
Patient diagnosed with mild, moderate or severe ARDS according to the Berlin classification based on the PaO₂/FiO₂ ratio, with a minimum PEEP set at 5 cmH₂O (16), of pulmonary aetiology:
- Mild ARDS: 200 < PaO₂/FiO₂ < 300 mmHg
- Moderate ARDS: 100 < PaO₂/FiO₂ < 200 mmHg
- Severe ARDS: PaO₂/FiO₂ < 100 mmHg
- Patients fitted with an oesophageal pressure measurement catheter (Nutrivent, Sidam, San Giacomo Roncole, Italy)
- Patients registered with or covered by a social security scheme
- Free and informed consent from the patient or a trusted relative (where the patient is unable to give consent).
Exclusion Criteria:
- Patients with a history of central nervous system disorders resulting in cognitive impairment
- Patients on ECMO
- Patients admitted for symptomatic central nervous system disorders
- Patients admitted for acute respiratory distress syndrome following cardiorespiratory arrest.
- Patients being treated for a psychiatric condition, chronic heavy drinkers, or those undergoing long-term treatment with benzodiazepines, antidepressants or antipsychotics.
- Pregnant, breastfeeding or labouring patients
- Individuals subject to a legal protection order
- Individuals receiving compulsory psychiatric care
- Individuals deprived of their liberty by judicial or administrative decision
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: cohort
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
|
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
association between the mechanical power between Day 1 and Day 3 (reflecting the risk of VILI)
Tidsramme: at day 1, day 2 and day 3
|
mechanical power calculation
|
at day 1, day 2 and day 3
|
|
S-100B serum protein level between Day 1 (H0) and Day 3 (H72).
Tidsramme: at day 1, day 2 and day 3
|
S-100B protein dosage
|
at day 1, day 2 and day 3
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
association between serum S100B protein concentrations from day 1 to day 3 and neurological outcome at 3 months and 12 months
Tidsramme: at 3 and 12 months
|
Correlation coefficient between S-100B protein levels from Day 1 to Day 3 and the MOCA (Montreal Cognitive Assessment) score at 3 and 12 months (no neurocognitive impairment if MOCA ≥ 26/30, neurocognitive impairment if < 25/30).
|
at 3 and 12 months
|
|
association between other VILI markers (inspiratory transpulmonary pressure and driving pressure) and serum S100B protein concentrations from day 1 to day 3.
Tidsramme: From day 1 to day 3
|
Correlation coefficient between inspiratory transpulmonary pressure and driving pressure, and serum S-100B levels between Day 1 and Day 3, whilst accounting for potential confounding factors in a multivariate model
|
From day 1 to day 3
|
|
association between these other VILI markers and neurological outcomes at 3 months and 12 months.
Tidsramme: at 3 and 12 months
|
Correlation coefficient between mechanical power, inspiratory transpulmonary pressure and driving pressure (average of values measured between J1 and J3) and the MOCA score at 3 and 12 months, taking potential confounding factors into account in a multivariate model
|
at 3 and 12 months
|
|
association between the occurrence of delirium during a stay in the intensive care unit and neurological outcomes at 3 and 12 months.
Tidsramme: at 3 and 12 months
|
The occurrence of neurocognitive impairment, defined as a MoCA score of <25/30 at the 3- and 12-month assessments, in patients who experienced delirium in the intensive care unit compared with those who did not.
|
at 3 and 12 months
|
|
prevalence of depression among patients who presented ARDS
Tidsramme: at 3 months
|
occurrence of depressive symptoms defined as a Patient Health Questionnaire-9 (PHQ-9) score > 10/27
|
at 3 months
|
|
prevalence of post-traumatic stress (PCL-5 score) among patients who presented ARDS
Tidsramme: at 3 months
|
occurrence of post-traumatic stress defined as a Post-Traumatic Stress Disorder Checklist dor DSM-5 (PCL-5) score > 33/80
|
at 3 months
|
|
prevalence of anxiety among patients who presented ARDS
Tidsramme: at 3 months
|
anxiety disorders defined as a General Anxiety Disorder-2 (GAD-2) score > 3/6
|
at 3 months
|
|
quality of life state (Euro 5d 5l score) among patients who presented ARDS
Tidsramme: at 3 months
|
deterioration in quality of life measured with EuroQol-5D-5L (max 5 points) :score analysed both continuously and categorically
|
at 3 months
|
|
prevalence of independence among patients who presented ARDS
Tidsramme: at 3 months
|
occurence of a decline in functional independence defined as the loss of at least one instrumental activity compared with the level prior to hospitalisation with the Instrumental Activities of Daily Living (IADL) score (from 8 to 30 max)
|
at 3 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 49RC25_0292
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Akutt respiratorisk distress syndrom (ARDS)
-
Ramos Mejía HospitalUniversidad de la RepublicaHar ikke rekruttert ennåRespiratory Distress Syndrome (RDS)
-
HTIC, IncRekrutteringARDS (Acute Respiratory Distress Syndrome)Forente stater
-
Vastra Gotaland RegionGöteborg UniversityHar ikke rekruttert ennåRespiratorisk distress syndrom hos premature spedbarn | Respiratory Distress Syndrome hos nyfødte | Respiratory Distress Syndrome (og [Hyaline Membrane Disease]) | Respiratory Distress Syndrome (RDS) | Respiratorisk nødsyndrom (neonatal)
-
Hospital Dr. Franco Ravera ZuninoHar ikke rekruttert ennåARDS (Acute Respiratory Distress Syndrome)
-
Wolfson Medical CenterUkjent
-
Christiana Care Health ServicesRekrutteringPreTerm nyfødt | Respiratory Distress Syndrome (RDS)Forente stater
-
Xingwang ZhuHunan Provincial People's Hospital; First People's Hospital of Chenzhou; Kunming... og andre samarbeidspartnereHar ikke rekruttert ennåBronkopulmonal dysplasi (BPD) | Respiratory Distress Syndrome (og [Hyaline Membrane Disease])
-
University of CalgaryHar ikke rekruttert ennåARDS (Acute Respiratory Distress Syndrome)
-
Ain Shams UniversityPåmelding etter invitasjonARDS (Acute Respiratory Distress Syndrome)Egypt
-
Ain Shams UniversityFullført
Kliniske studier på Blood test scores calculations
-
University of California, DavisNational Cancer Institute (NCI)Har ikke rekruttert ennåEndetarmskreft | Rektal adenokarsinom | Lokalt avansert rektal adenokarsinom | Tidlig stadium endetarmskreftForente stater
-
Javier ToledoRekrutteringTykktarmskreft | Eggstokkreft | Leverkarsinom | Glioblastom (GBM) | Bukspyttkjertelkreft, voksen | Lungekreft (NSCLC) | Prostatakreft | Brest kreftArgentina, Nigeria, Storbritannia
-
Syntrillo, IncHar ikke rekruttert ennåHypertensjon | Kardiovaskulær risikofaktor | Slagforebygging | Hypertensjon (HTN)
-
National Cancer Institute (NCI)RekrutteringStadium IV lungekreft AJCC v8 | Stadium IIIB lungekreft AJCC v8 | Avansert lunge ikke-plateepitel, ikke-småcellet karsinom | Metastatisk lunge, ikke-plateepitel, ikke-småcellet karsinom | Tilbakevendende lunge ikke-plateepitel, ikke-småcellet karsinomForente stater